Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis

Drug Development Research

Volumn 76, Issue 4, 2015, Pages 204-214

  Fatani, Amal J ^a   Al Hosaini, Khaled A ^a   Ahmed, Mohammed M ^a   Abuohashish, Hatem M ^a,b   Parmar, Mihir Y ^a   Al Rejaie, Salim S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

carvedilol; inflammatory bowel disease; oxidative stress; ulcerative colitis

Indexed keywords

ACETIC ACID; ANTIOXIDANT; BIOLOGICAL MARKER; CARVEDILOL; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESALAZINE; NITRIC OXIDE; PROSTAGLANDIN E2; THIOL GROUP; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CARBAZOLE DERIVATIVE; DNA; MALONALDEHYDE; PROPANOLAMINE DERIVATIVE; RNA; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; COLON; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; ULCERATIVE COLITIS; ANIMAL; COLITIS, ULCERATIVE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MUCUS; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOMARKERS; CARBAZOLES; COLITIS, ULCERATIVE; COLON; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; DNA; MALE; MALONDIALDEHYDE; MUCUS; NITRIC OXIDE; OXIDATIVE STRESS; PROPANOLAMINES; RATS, WISTAR; RNA; SULFHYDRYL COMPOUNDS;

EID: 84932647204     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21256     Document Type: Article

References (64)

1. Ademoglu E, Erbil Y, Tam B, Barbaros U, Ilhan E, Olgac V, Mutlu-Turkoglu U., 2004. Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci 49: 102-108.
2. Aebi H., 1974. Catalase. In:, Bergmeyer HV, editor. Methods in enzymatic analysis. New York: Academic press, p 674-684.
3. Al-Rejaie SS., 2009. Inhibition of ethanol-induced gastric mucosal damage by Carv in male Wistar albino rats: possible biochemical changes. Int J Pharmacol 5: 146-154.
4. Al-Rejaie SS, Abuohashish HM, Ahmed MM, Aleisa AM, Alkhamees O., 2012. Possible biochemical effects following inhibition of ethanol-induced gastric mucosa damage by Gymnema sylvestre in male Wistar albino rats. Pharm Biol 50: 1542-1550.
5. Baumgart DC, Sandborn WJ., 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
6. Bertevello PL, Logullo AF, Nonogaki S, Campos FM, Chiferi V, Alves CC, Torrinhas RS, Gama-Rodrigues JJ, Waitzberg DL., 2005. Immunohistochemical assessment of mucosal cytokine profile in acetic acid experimental colitis. Clinics (Sao Paulo) 60: 277-286.
7. Bitiren M, Karakilcik AZ, Zerin M, Ozardali I, Selek S, Nazligul Y, Ozgonul A, Musa D, Uzunkoy A., 2010. Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res 136: 87-95.
8. Bregman A., 1983. Laboratory investigation and cell biology. New York: Wiley.
9. Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG., 2010. Hospitalized prevalence and 5-year mortality for IBD: record linkage study. World J Gastroenterol 16: 431-438.
10. Cargnoni A, Ceconi C, Bernocchi P, Boraso A, Parrinello G, Curello S, Ferrari R., 2000. Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. Cardiovasc Res 47: 556-566.
11. Cetinkaya A, Bulbuloglu E, Kantarceken B, Ciralik H, Kurutas EB, Buyukbese MA, Gumusalan Y., 2006. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci 51: 488-494.
12. Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B, Buyukbese MA., 2005. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med 206: 131-139.
13. Cleland JG, Swedberg K., 1996. Carvedilol for heart failure, with care. Lancet 347: 1199-1201.
14. Communal C, Colucci WS., 2005. The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways. Arch Mal Coeur Vaiss 98: 236-241.
15. Das S, Kanodia L, Mukherjee A, Hakim A., 2013. Effect of ethanolic extract of leaves of Paederia foetida Linn. on acetic acid induced colitis in albino rats. Indian J Pharmacol 45: 453-457.
16. de Araujo Junior RF, Souza TO, de Medeiros CA, de Souza LB, Freitas Mde L, de Lucena HF, do Socorro Costa Feitosa Alves M, de Araujo AA., 2013. Carvedilol decrease IL-1beta and TNF-alpha, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis. PLoS One 8: e66391.
17. Droge W., 2002. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95.
18. Duerr RH., 2003. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 37: 358-367.
19. Dulin B, Abraham WT., 2004. Pharmacology of carvedilol. Am J Cardiol 93: 3B-6B.
20. El-Abhar HS, Hammad LN, Gawad HS., 2008. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol 118: 367-372.
21. Grisham MB., 1994. Oxidants and free radicals in inflammatory bowel disease. Lancet 344: 859-861.
22. Grisham MB, Yamada T., 1992. Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann N Y Acad Sci 664: 103-115.
23. Hakucho A, Liu J, Liu X, Fujimiya T., 2014. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res 44: 560-570.
24. Hamalainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E., 2007. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007: 45673.
25. Harputluoglu MM, Demirel U, Yucel N, Karadag N, Temel I, Firat S, Ara C, Aladag M, Karincaoglu M, Hilmioglu F., 2006. The effects of Gingko biloba extract on acetic acid-induced colitis in rats. Turk J Gastroenterol 17: 177-182.
26. Huang H, Shan J, Pan XH, Wang HP, Qian LB, Xia Q., 2007. Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Res Clin Pract 75: 7-13.
27. Iacucci M, de Silva S, Ghosh S., 2010. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol 24: 127-133.
28. Kannan N, Guruvayoorappan C., 2013. Protective effect of Bauhinia tomentosa on acetic acid induced ulcerative colitis by regulating antioxidant and inflammatory mediators. Int Immunopharmacol 16: 57-66.
29. Kono Y., 1978. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186: 189-195.
30. Kopecky SL., 2006. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 98: 1115-1119.
31. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA., 2004. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 49: 1433-1437.
32. Kumar A, Dogra S., 2009. Neuroprotective effect of carvedilol, an adrenergic antagonist against colchicine induced cognitive impairment and oxidative damage in rat. Pharmacol Biochem Behav 92: 25-31.
33. Kumar A, Prakash A, Dogra S., 2011. Neuroprotective effect of carvedilol against aluminium induced toxicity: possible behavioral and biochemical alterations in rats. Pharmacol Rep 63: 915-923.
34. Kurutas EB, Cetinkaya A, Bulbuloglu E, Kantarceken B., 2005. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators Inflamm 2005: 390-394.
35. Lakatos PL., 2006. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 12: 6102-6108.
36. Le DE, Pascotto M, Leong-Poi H, Sari I, Micari A, Kaul S., 2013. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol 108: 384.
37. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, et al., 1996. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 41: 2078-2086.
38. Loftus EV Jr., 2004. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126: 1504-1517.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ., 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
40. Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani FS, Ghafourifar P., 2009. Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats. Eur J Clin Invest 39: 375-383.
41. Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K, et al., 2006. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol 290: G361-G368.
42. Oz HS, Chen TS, McClain CJ, de Villiers WJ., 2005. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 16: 297-304.
43. Park MY, Ji GE, Sung MK., 2012. Dietary kaempferol suppresses inflammation of dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 57: 355-363.
44. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB., 2002. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33: 311-322.
45. Popov SV, Markov PA, Nikitina IR, Petrishev S, Smirnov V, Ovodov YS., 2006. Preventive effect of a pectic polysaccharide of the common cranberry Vaccinium oxycoccos L. on acetic acid-induced colitis in mice. World J Gastroenterol 12: 6646-6651.
46. Prakash AK, Kumar A., 2009. Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 61: 1665-1672.
47. Pravda J., 2005. Radical induction theory of ulcerative colitis. World J Gastroenterol 11: 2371-2384.
48. Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R., 2001. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68: 921-931.
49. Rezaie A, Parker RD, Abdollahi M., 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52: 2015-2021.
50. Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC., 2011. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 189: 45-51.
51. Ruffolo RR Jr, Feuerstein GZ., 1997. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 11 (Suppl. 1): 247-256.
52. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ., 1990. The pharmacology of carvedilol. Eur J Clin Pharmacol 38 (Suppl. 2): S82-S88.
53. Savitz SI, Erhardt JA, Anthony JV, Gupta G, Li X, Barone FC, Rosenbaum DM., 2000. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 20: 1197-1204.
54. Sedlak J, Lindsay RH., 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25: 192-205.
55. Strober W, Ludviksson BR, Fuss IJ., 1998. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann Intern Med 128: 848-856.
56. Stucchi A, Reed K, O'Brien M, Cerda S, Andrews C, Gower A, Bushell K, Amar S, Leeman S, Becker J., 2006. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis 12: 581-587.
57. Tahan G, Aytac E, Aytekin H, Gunduz F, Dogusoy G, Aydin S, Tahan V, Uzun H., 2011. Vitamin E has a dual effect of anti-inflammatory and antioxidant activities in acetic acid-induced ulcerative colitis in rats. Can J Surg 54: 333-338.
58. Tijani AY, Salawu OA, Uboho UE., 2013. Neuro-protective effect of Carvedilol, an adrenergic antagonist against scopolamine-induced cognitive impairment in mice. J Appl Pharm Sci 3: S32-S36.
59. Tuzun A, Erdil A, Inal V, Aydin A, Bagci S, Yesilova Z, Sayal A, Karaeren N, Dagalp K., 2002. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 35: 569-572.
60. Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, Stefanadis CI., 2004. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens 17: 582-589.
61. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL., 2006. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 98: 32L-38L.
62. Xavier RJ, Podolsky DK., 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
63. Yasar A, Erdemir F, Parlaktas BS, Atilgan D, Koseoglu RD, Saylan O, Firat F., 2013. The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model. Kaohsiung J Med Sci 29: 19-25.
64. Yu BP., 1994. Cellular defenses against damage from reactive oxygen species. Physiol Rev 74: 139-162.